Serum Lactate Dehydrogenase Levels as a Predictive Marker of Oxaliplatin-Induced Hypersensitivity Reactions in Japanese Patients with Advanced Colorectal Cancer

Seki, Kyoko; Tsuduki, Yasuo; Ioroi, Takeshi; Yamane, Michiko; Yamauchi, Hiroko; Shiraishi, Yukinari; Ogawa, Tadaaki; Nakata, Izumi; Nishiguchi, Kohshi; Matsubayashi, Teruhisa; Takakubo, Yoshihide; Yamamori, Motohiro; Kuwahara, Akiko; Okamura, Noboru; Sakaeda, Toshiyuki

doi:10.7150/ijms.7643

Cited by 11 publications

(7 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally it has been shown that serum LDH levels could be also valuable to predict hypersensitivity reactions in colorectal cancer patients treated with the platinum anticancer agent, oxaliplatin (L-OHP) (99). In addition, Koukourakis et al reported that tissue LDHA was associated with resistance to standard chemotherapy, poor progression-free survival and high performance status in patients with advanced colorectal cancer (CRC) (100).…”

Section: Ldh As Diagnostic Marker Prognostic Factor and Predictive Mmentioning

confidence: 99%

Lactic dehydrogenase and cancer an overview

Gallo¹,

Sapio²,

Spina

et al. 2015

Front Biosci

View full text Add to dashboard Cite

Despite the intense scientific efforts made, there are still many tumors that are difficult to treat and the percentage of patient survival in the long-term is still too low. Thus, new approaches to the treatment of cancer are needed. Cancer is a highly heterogeneous and complex disease, whose development requires a reorganization of cell metabolism. Most tumor cells downregulate mitochondrial oxidative phosphorylation and increase the rate of glucose consumption and lactate release, independently of oxygen availability (Warburg effect). This metabolic rewiring is largely believed to favour tumor growth and survival, although the underlying molecular mechanisms are not completely understood. Importantly, the correlation between the aerobic glycolysis and cancer is widely regarded as a useful biochemical basis for the development of novel anticancer strategies. Among the enzymes involved in glycolysis, lactate dehydrogenase (LDH) is emerging as a very attractive target for possible pharmacological approaches in cancer therapy. This review addresses the state of the art and the perspectives concerning LDH both as a useful diagnostic marker and a relevant molecular target in cancer therapy and management.

show abstract

Section: Ldh As Diagnostic Marker Prognostic Factor and Predictive Mmentioning

confidence: 99%

Lactic dehydrogenase and cancer an overview

Gallo¹,

Sapio²,

Spina

et al. 2015

Front Biosci

View full text Add to dashboard Cite

show abstract

“…In Japan, one study revealed that serum lactate dehydrogenase (LDH) levels at the beginning of chemotherapy might predict IHSRs to oxaliplatin [20], and a Korean study suggested that the amount of dexamethasone used as premedication could predict IHSRs [21]. Further studies, however, are needed to confirm the reliability of these factors.…”

Section: Discussionmentioning

confidence: 99%

A New Practical Desensitization Protocol for Oxaliplatin-Induced Immediate Hypersensitivity Reactions: A Necessary and Useful Approach

Kim

et al. 2016

J Investig Allergol Clin Immunol

View full text Add to dashboard Cite

Background and Objective: Desensitization protocols for patients with immediate hypersensitivity reactions (IHSRs) have proven to be effective, but they are not widely used in clinical practice because of impracticalities such as high cost, long procedure duration, and a lack of trained personnel. We aimed to determine the clinical characteristics of oxaliplatin-induced IHSRs and assess measures to protect against these reactions and to validate a new practical desensitization protocol. Methods: We retrospectively reviewed 2640 cases of oxaliplatin IHSRs in 271 oxaliplatin users and prospectively used a newly designed desensitization protocol 32 times in 12 patients with hypersensitivity to platinum-based chemotherapy. The protocol consisted of increases in infusion rate every 15 minutes, regardless of the concentration of the chemotherapy agent in the infusion bags. Results: Of the 271 patients administered oxaliplatin, 45 (16.6%) experienced IHSRs. Of 39 patients who experienced an IHSR but needed to continue oxaliplatin, 6 (15.4%) stopped treatment due to the reaction, and 33 (84.6%) continued despite the risk of further reactions. The new desensitization protocol was successfully completed in 12 patients (100%), but it was ineffective in 3 patients (all with a negative skin prick test), who experienced fever without urticaria. Conclusions: Many patients who experience oxaliplatin-induced IHSRs are required to stop first-line oxaliplatin-based chemotherapy or to continue without desensitization, with the associated risks. Our new desensitization protocol is practical and easy to use in clinical practice.

show abstract

“…Normally LDH exists in almost all cytoplasm, it plays an important role in producing cell energe including cancer cells. (Seki et al, 2014). LDH can't be released into the extracellular through the cell membrance, but, this cytosolic enzyme can be released if the cell was injuried or dead.…”

Section: Discussionmentioning

confidence: 99%

Preliminary Evaluation of the in vitro Efficacy of 1, 2-di (Quinazolin-4-yl) Diselane against SiHa Cervical Cancer Cells

Huang

Zhang²,

Liu³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Cervical cancer is one the most common malignancies among females. In recent years, its incidence rate has shown a rising trend in some countries so that development of anticancer drugs for cervical cancer is an urgent priority. In our recent anticancer drug discovery screen, 1, 2-di (quinazolin-4-yl)diselane (LG003) was found to possess wide spectrum anticancer efficacy. In the present work, the in vitro anticancer activity of LG003 was evaluated in the SiHa cervical cancer cell line. Compared with commercial anticancer drugs 10-hydroxycamptothecin, epirubicin hydrochloride, taxol and oxaliplatin, LG003 showed better anticancer activity. Furthermore, inhibition effects were time-and dose-dependent. Morphological observation exhibited LG003 treatment results in apoptosis like shrinking and blebbing, and cell membrane damage. Lactate dehydrogenase release assay revealed that LG003 exerts such effects in SiHa cells through a physiology pathway rather than cytotoxicity, which suggests that title compound LG003 can be a potential candidate agent for cervical cancer.

show abstract

Serum Lactate Dehydrogenase Levels as a Predictive Marker of Oxaliplatin-Induced Hypersensitivity Reactions in Japanese Patients with Advanced Colorectal Cancer

Cited by 11 publications

References 30 publications

Lactic dehydrogenase and cancer an overview

Lactic dehydrogenase and cancer an overview

A New Practical Desensitization Protocol for Oxaliplatin-Induced Immediate Hypersensitivity Reactions: A Necessary and Useful Approach

Preliminary Evaluation of the in vitro Efficacy of 1, 2-di (Quinazolin-4-yl) Diselane against SiHa Cervical Cancer Cells

Contact Info

Product

Resources

About